Mandate

Vinge advises AstraZeneca

January 30, 2013

Vinge has advised AstraZeneca in connection with the sale of its research facility in Södertälje to Acturum, a group formed by FAM, the Wallenber foundations’ management company, and PEAB. The transaction covers, among other things, real estate, laboratories, research projects and a significant number of laboratory equipment and is intended to create conditions for future research and enterprise within the entire filed of life science.

Vinge’s team consisted of responsible partner Malin Ohlin and associate Kristina Ekberg and also included partner Patrick Forslund and associates Daniel Unger, Johan Cederblad, Nazli Zia, Peter Alstergren, Claes Henriksson and project assistant Sara Andersson.

Related

Vinge advises Symrise on its public offer for Probi

Symrise AG has announced a public cash offer to the shareholders of Probi AB (publ) (“Probi”). The offer values Probi at approximately SEK 3,988 million. The shares in Probi are traded on Nasdaq Stockholm, Mid Cap.
November 20, 2024

Vinge advises Oxx in conjunction with an investment in Kodiak Hub

Kodiak Hub, a Swedish software as a service (SaaS) company, which offers its customers an AI-based software platform, has performed a capital procurement of EUR 6 million. The venture capital fund Oxx, which invests in SaaS companies, is the largest investor.
November 20, 2024

Vinge advises HAKI Safety AB (publ) in connection with the acquisition of Semmco Group Limited

Semmco Group is a UK market-leading manufacturer and supplier of maintenance platforms and stairs for aircraft and trains.
November 19, 2024